Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine parainfluenza; leptospira icterohaemorrhagiae antigen; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine parainfluenza vaccine active 0.0 undefined; leptospira icterohaemorrhagiae antigen vaccine-antigen active 0.0 undefined; canine adeno virus type 2 vaccine-viral active 0.0 undefined; canine coronavirus vaccine - antigen vaccine-viral active 0.0 undefined; canine distemper virus vaccine-viral active 0.0 undefined; canine parvo virus vaccine-viral active 0.0 undefined - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 25 mg - tablet, multilayer - excipient ingredients: maize starch; sorbitol; sodium hydroxide; iron oxide yellow; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; meglumine - micardis plus is indicated for the treatment of hypertension. treatment should not be intitiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sodium hydroxide; sorbitol; microcrystalline cellulose; iron oxide red; maize starch; lactose monohydrate; povidone; sodium starch glycollate - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: povidone; sodium hydroxide; microcrystalline cellulose; lactose monohydrate; sorbitol; sodium starch glycollate; maize starch; meglumine; magnesium stearate; iron oxide red - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 180.6 mg (equivalent: nintedanib, qty 150 mg) - capsule, soft - excipient ingredients: iron oxide red; titanium dioxide; hard fat; lecithin; gelatin; glycerol; iron oxide yellow; medium chain triglycerides; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - nintedanib esilate, quantity: 120.4 mg (equivalent: nintedanib, qty 100 mg) - capsule, soft - excipient ingredients: hard fat; lecithin; glycerol; iron oxide red; gelatin; medium chain triglycerides; titanium dioxide; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ofev is indicated in combination with docetaxel for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (nsclc) of adenocarcinoma tumour histology after failure of first line chemotherapy.,ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf).,ofev is also indicated for the treatment of other chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype.,ofev is indicated for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-ild).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - ipratropium bromide monohydrate, quantity: 21 microgram/actuation - inhalation, pressurised - excipient ingredients: ethanol absolute; citric acid; purified water; norflurane - atrovent metered aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with asthma and chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - dipyridamole -

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium hydroxide; sorbitol; meglumine - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sorbitol; sodium hydroxide; povidone; meglumine; magnesium stearate - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)